These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 26271395)

  • 21. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
    Marthey L; Sa-Cunha A; Blanc JF; Gauthier M; Cueff A; Francois E; Trouilloud I; Malka D; Bachet JB; Coriat R; Terrebonne E; De La Fouchardière C; Manfredi S; Solub D; Lécaille C; Thirot Bidault A; Carbonnel F; Taieb J
    Ann Surg Oncol; 2015 Jan; 22(1):295-301. PubMed ID: 25037971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complete radiological response of an initially locally advanced unresectable pancreatic cancer to chemoradiotherapy using FOLFIRINOX regimen: report of a case.
    Turner K; Levi Sandri GB; Boucher E; Hénno S; Le Prisé E; Meunier B; Boudjema K; Sulpice L
    Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):e29-31. PubMed ID: 25288453
    [No Abstract]   [Full Text] [Related]  

  • 23. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma.
    McIntyre CA; Cohen NA; Goldman DA; Gonen M; Sadot E; O'Reilly EM; Varghese AM; Yu KH; Balachandran VP; Soares KC; D'Angelica MI; Drebin JA; Kingham TP; Allen PJ; Wei AC; Jarnagin WR
    J Surg Oncol; 2022 Mar; 125(3):425-436. PubMed ID: 34719035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
    Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
    Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
    Zahir MN; Jabbar AA
    Asian Pac J Cancer Prev; 2015; 16(14):6001-6. PubMed ID: 26320487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma.
    Sadot E; Doussot A; O'Reilly EM; Lowery MA; Goodman KA; Do RK; Tang LH; Gönen M; D'Angelica MI; DeMatteo RP; Kingham TP; Jarnagin WR; Allen PJ
    Ann Surg Oncol; 2015 Oct; 22(11):3512-21. PubMed ID: 26065868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.
    Truty MJ; Kendrick ML; Nagorney DM; Smoot RL; Cleary SP; Graham RP; Goenka AH; Hallemeier CL; Haddock MG; Harmsen WS; Mahipal A; McWilliams RR; Halfdanarson TR; Grothey AF
    Ann Surg; 2021 Feb; 273(2):341-349. PubMed ID: 30946090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
    Mahaseth H; Brutcher E; Kauh J; Hawk N; Kim S; Chen Z; Kooby DA; Maithel SK; Landry J; El-Rayes BF
    Pancreas; 2013 Nov; 42(8):1311-5. PubMed ID: 24152956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen.
    Garnier J; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Giovannini M; Poizat F; Delpero JR; Turrini O
    Eur J Surg Oncol; 2020 Aug; 46(8):1510-1515. PubMed ID: 32146053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
    Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS
    Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
    Peddi PF; Lubner S; McWilliams R; Tan BR; Picus J; Sorscher SM; Suresh R; Lockhart AC; Wang J; Menias C; Gao F; Linehan D; Wang-Gillam A
    JOP; 2012 Sep; 13(5):497-501. PubMed ID: 22964956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.
    Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R
    Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study.
    Suker M; Nuyttens JJ; Groot Koerkamp B; Eskens FALM; van Eijck CHJ
    J Surg Oncol; 2018 Nov; 118(6):1021-1026. PubMed ID: 30259526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?
    He J; Blair AB; Groot VP; Javed AA; Burkhart RA; Gemenetzis G; Hruban RH; Waters KM; Poling J; Zheng L; Laheru D; Herman JM; Makary MA; Weiss MJ; Cameron JL; Wolfgang CL
    Ann Surg; 2018 Jul; 268(1):1-8. PubMed ID: 29334562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort.
    Auclin E; Marthey L; Abdallah R; Mas L; Francois E; Saint A; Cunha AS; Vienot A; Lecomte T; Hautefeuille V; de La Fouchardière C; Sarabi M; Ksontini F; Forestier J; Coriat R; Fabiano E; Leroy F; Williet N; Bachet JB; Tougeron D; Taieb J
    Br J Cancer; 2021 Jun; 124(12):1941-1948. PubMed ID: 33772154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
    Faris JE; Blaszkowsky LS; McDermott S; Guimaraes AR; Szymonifka J; Huynh MA; Ferrone CR; Wargo JA; Allen JN; Dias LE; Kwak EL; Lillemoe KD; Thayer SP; Murphy JE; Zhu AX; Sahani DV; Wo JY; Clark JW; Fernandez-del Castillo C; Ryan DP; Hong TS
    Oncologist; 2013; 18(5):543-8. PubMed ID: 23657686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis.
    Baldini C; Escande A; Bouché O; El Hajbi F; Volet J; Bourgeois V; Renaut Vantroys T; Ploquin A; Desauw C; Hebbar M
    Pancreatology; 2017; 17(1):146-149. PubMed ID: 28040425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
    Nanda RH; El-Rayes B; Maithel SK; Landry J
    J Surg Oncol; 2015 Jun; 111(8):1028-34. PubMed ID: 26073887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.